Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 23 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

30%

7 trials in Phase 3/4

Results Transparency

5%

1 of 20 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
10(43.5%)
Phase 3
7(30.4%)
Phase 1
6(26.1%)
23Total
N/A(10)
Phase 3(7)
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT07070752Phase 3Completed

Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients

Role: lead

NCT05648799Not ApplicableCompleted

Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia)

Role: lead

NCT04268472Not ApplicableCompleted

Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson&Jonson", Russia)

Role: lead

NCT06497036Phase 3Active Not Recruiting

Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia

Role: lead

NCT06497049Phase 1Completed

Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®.

Role: lead

NCT06050343Not ApplicableCompleted

Comparative Study of Rinsulin R (GEROPHARM) and Humulin Regular (Eli Lilly) Euglycemic Hyperinsulinemic Clamp Method

Role: lead

NCT05652595Phase 1Unknown

Double-blind, Randomized Comparative Cross-sectional Study of Pharmacodynamics and Pharmacokinetics of Drugs GP40141

Role: lead

NCT04501250Not ApplicableCompleted

Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method

Role: lead

NCT04498884Not ApplicableCompleted

Comparative Study of the Pharmacokinetics of Rinsulin® Mix 30/70, Suspension for Subcutaneous Administration, 100 IU / ml (OJSC GEROPHARM-Bio, Russia) and Humulin® M3, Suspension for Subcutaneous Administration, 100 IU / ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method

Role: lead

NCT04079413Phase 3Completed

Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients

Role: lead

NCT04226105Phase 3Unknown

Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients

Role: lead

NCT04184492Not ApplicableCompleted

A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects

Role: lead

NCT04184466Not ApplicableCompleted

A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Aspart to NovoRapid® Penfill® in Healthy Subjects

Role: lead

NCT04101383Not ApplicableCompleted

A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients

Role: lead

NCT04101370Phase 1Completed

Bioequivalence Study of Bosentan 125 mg Tablets Immediate Release (IR) Versus Tracleer® 125 mg Tablets IR In Healthy Subjects

Role: lead

NCT04022993Phase 3Completed

Efficacy and Safety of Insulin RinGlar® Compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients

Role: lead

NCT04023344Phase 3Completed

Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients

Role: lead

NCT04012775Phase 3Completed

Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients

Role: lead

NCT03121820Phase 1Completed

Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects

Role: lead

NCT03606018Not ApplicableCompleted

A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mix 25 to Humalog® Mix 25 in Healthy Subjects

Role: lead